# OnCo record fushi-biotechnology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/fushi-biotechnology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "fushi-biotechnology" ;
  schema:name "Fushi Biotechnology"@en ;
  schema:alternateName "Foresight Therapeutics (Hefei) Co., Ltd."@en, "Jiangsu Fushi Biotechnology Co., Ltd."@en, "江苏福石生物科技有限公司"@en, "福石生物"@en ;
  schema:description "Fushi Biotechnology makes small-molecule tablet drugs found by building them up from tiny chemical fragments. Its first cancer drug, FS-207, blocks WRN, a DNA-unwinding enzyme that tumours with a particular DNA repair defect (MSI-high) depend on, and is starting early trials in China."@en ;
  schema:url <https://onco.cc/companies/fushi-biotechnology/>, <https://www.foresightbiopharm.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.foresightbiopharm.com/>, <https://www.foresightbiopharm.com/company_news/76.html>, <https://clinicaltrials.gov/study/NCT07593144> ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/wrn/> .